Emergency / crisis support: /emergency
CANSA Toll-Free: 0800 22 6622
If your medical aid has declined a claim, refused a biologic, or exhausted its oncology sub-limit — this guide outlines the specific steps to take now.
Common Colorectal Cancer Financial Crises
1. Bevacizumab or pembrolizumab exceptional-needs declined Your oncologist recommended targeted therapy or immunotherapy; your scheme has refused.
2. Oncology sub-limit exhausted mid-treatment The annual oncology rand cap has been reached; the scheme is refusing further chemotherapy costs.
3. Outstanding surgical shortfall A large unpaid balance remains from the colorectal surgeon, anaesthesiologist, or hepatobiliary surgeon.
4. Biomarker test claim rejected KRAS/MSI testing was processed as non-covered or charged to the incorrect benefit category.
5. Oral capecitabine classified incorrectly Capecitabine processed under the drug benefit with a co-payment rather than as oncology PMB.
If Bevacizumab Was Declined
Step 1: Get written reasons for the decline. Oral refusals are not a formal denial — the scheme must provide written clinical and/or formulary reasons.
Step 2: Ask your oncologist to prepare a structured exceptional-needs motivation: - Staging (TNM classification) - KRAS/NRAS wild-type result (mandatory for bevacizumab consideration) - ECOG performance status - Specific FOLFOX/CAPOX + bevacizumab protocol reference - Published survival data (TREE-1/2, AVF2107 trials for bevacizumab in mCRC)
Step 3: Request a peer-to-peer review between your oncologist and the scheme's medical advisor. This single step resolves many exceptional-needs disputes without formal appeal.
Step 4: If still declined, submit a formal internal appeal. Request the scheme's formal appeals procedure and SLA timelines.
Step 5: Escalate to the Council for Medical Schemes (CMS) if the internal appeal fails. CMS adjudication is free, binding, and takes approximately 4–8 weeks.
If Pembrolizumab Was Declined (MSI-H/dMMR Confirmed)
If your tumour is confirmed MSI-H/dMMR and your oncologist recommends pembrolizumab, the clinical evidence for first-line use is strong (KEYNOTE-177 trial data; NCCN Category 1 recommendation). A scheme declining pembrolizumab for confirmed MSI-H/dMMR metastatic colorectal cancer has a weak clinical position.
Include the MSI-H/dMMR molecular confirmation in your exceptional-needs documentation. This biomarker result is the clinical predicate for the treatment — without it, the application will fail; with it, approval rates improve substantially.
If Your Oncology Sub-Limit Has Run Out
First, determine whether the ongoing treatment is PMB-classified. Adjuvant FOLFOX/CAPOX chemotherapy is the PMB minimum treatment standard for Stage III and is a primary treatment for Stage IV. Oncology sub-limits do not extinguish the scheme's PMB obligation for PMB-classified treatment.
Write to your scheme: name the specific treatment, state it is the PMB minimum treatment standard for your stage and tumour profile, and request confirmation that it will continue to be funded despite the sub-limit being reached. Include your oncologist's written confirmation.
If the scheme disputes PMB classification, escalate immediately to the CMS. PMB oncology disputes are adjudicated relatively quickly and the scheme bears the burden of proving the treatment is not the minimum standard.
If Capecitabine Is Being Processed Incorrectly
Oral capecitabine when used as adjuvant or palliative chemotherapy for colorectal cancer is the functional equivalent of IV 5-FU. It should be processed as oncology PMB, not as a chronic discretionary drug benefit.
If your scheme is applying a chronic drug benefit co-payment or formulary restriction to capecitabine prescribed for colorectal cancer, write to case management requesting that it be reclassified to your oncology benefit and processed at 100% without co-payment under PMB regulations.
Outstanding Surgical Shortfalls
If you have a large outstanding account from your colorectal surgeon or anaesthesiologist:
- Request fully itemised invoices from the surgeon's billing office and the hospital.
- Compare line items against your medical aid remittance advice — identify which items the scheme paid and at what rate.
- Check whether the procedure was properly pre-authorised. An improperly processed pre-authorisation on the scheme side can result in claims being rejected that should have been approved.
- Contact the surgeon's practice manager and request a payment arrangement for the shortfall.
- If the shortfall is above gap cover OPL (R220,000/year), the balance is out-of-pocket — negotiate with both the specialist and the scheme on whether the original claim was processed correctly.
Triage: Priority Actions
| Situation | Priority | Action |
|---|---|---|
| Exceptional-needs declined (bevacizumab/pembrolizumab) | High | Written appeal + peer-to-peer + CMS |
| Sub-limit hit on PMB-classified chemo | Urgent | PMB letter to case management + oncologist confirmation |
| Capecitabine on wrong benefit | Medium | Written reclassification request to case management |
| Biomarker test rejected | Medium | Submit with correct billing codes; dispute if declined |
| Surgical shortfall outstanding | Medium | Itemised invoice review + payment plan |
| Gap OPL (R220,000) exhausted | Informational | No further gap cover; remaining shortfalls are out-of-pocket |
Escalation Contacts
Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.org.za CANSA: 0800 22 6622 (toll-free) Colostomy Association of South Africa: www.colostomy.co.za AURA Emergency: /emergency
Talk to Eldon
Get urgent help with your cover situation →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).